Get Your Personalized Supplement StackSupplement Stack Quiz

Echinacea Purpurea Extract

Also known as: Echinacea purpurea, Purple Coneflower, American Coneflower

Overview

Echinacea purpurea, commonly known as Purple Coneflower, is a flowering plant native to North America. It is widely used in herbal medicine for its purported immune-boosting properties. The plant's roots, leaves, and flowers are utilized in various preparations, including extracts and capsules. Primarily, Echinacea purpurea is used to prevent and treat upper respiratory tract infections (URTIs), such as the common cold. Research on Echinacea purpurea is extensive, but the quality varies, with some systematic reviews and meta-analyses providing more robust evidence. While it is generally considered safe for short-term use, variability in product quality and methodological heterogeneity remain challenges in fully assessing its efficacy.

Benefits

Echinacea purpurea has demonstrated potential benefits in reducing the incidence and duration of upper respiratory tract infections (URTIs). A meta-analysis indicated that Echinacea purpurea significantly reduces the incidence of URTIs (RR = 0.81, 95% CI [0.75; 0.87]) and shortens treatment duration (SMD = -0.19, 95% CI [-0.30; -0.09]) in children. Another study showed a preventive effect on URTIs with a risk ratio of 0.78 (95% CI 0.68-0.88). Furthermore, it may reduce antibiotic use, particularly in children (RR = 0.18, 95% CI [0.13; 0.25]). These benefits are more pronounced in children, suggesting a population-specific advantage.

How it works

Echinacea purpurea is believed to modulate immune responses, primarily by enhancing innate immunity. It may also influence cytokine production, which plays a crucial role in immune cell activity and inflammation. The exact molecular targets are not well-defined, but Echinacea purpurea interacts with the immune system, potentially influencing inflammation and immune cell activity. The bioavailability of its compounds varies depending on the preparation and form of administration, affecting its overall effectiveness.

Side effects

Echinacea purpurea is generally considered safe for short-term use, but some side effects have been reported. Common side effects include mild gastrointestinal symptoms and allergic reactions. Uncommon side effects, occurring in 1-5% of users, may include more severe allergic reactions or interactions with medications. Severe allergic reactions are rare. Echinacea purpurea may interact with immunosuppressants or other medications affecting the immune system. It is contraindicated in individuals with autoimmune diseases or those taking immunosuppressive drugs. Caution is advised in pregnant or breastfeeding women due to limited data. Overall, the safety profile is favorable, but awareness of potential adverse effects and interactions is essential.

Dosage

Typical doses of Echinacea purpurea range from 300 to 500 mg per day, though optimal dosage varies by preparation. Extracts are often standardized to contain specific levels of active compounds. While a maximum safe dose is not clearly defined, high doses are generally not recommended without medical supervision. It is often taken at the onset of cold symptoms or as a preventive measure. Capsules, tablets, or liquid extracts are common forms. Bioavailability may be influenced by the form of administration and individual metabolism. There are no specifically identified required cofactors.

FAQs

Is Echinacea purpurea safe?

Generally safe for short-term use, but consult a healthcare provider if you have autoimmune conditions or are taking immunosuppressants.

When should I take Echinacea purpurea?

Start at the onset of cold symptoms or as a preventive measure during cold and flu season.

What are the expected results from taking Echinacea purpurea?

It may reduce the incidence and duration of upper respiratory tract infections (URTIs), such as the common cold.

Does Echinacea purpurea cure colds?

No, it is not a cure for colds, but it may help prevent or shorten their duration by modulating the immune response.

Research Sources

https://pmc.ncbi.nlm.nih.gov/articles/PMC7106401/ – This meta-analysis of 14 studies with 1356 participants found that Echinacea decreased the odds of developing the common cold by 58% (OR 0.42, 95% CI 0.25–0.71). The study acknowledges heterogeneity among included studies and variability in echinacea preparations, highlighting the need for standardized research.
https://pubmed.ncbi.nlm.nih.gov/31126553/ – This systematic review and meta-analysis suggests that Echinacea may have a preventive effect on URTIs (RR = 0.78, 95% CI 0.68-0.88). The review used Cochrane quality assessment tools but noted clinical heterogeneity and a risk of selective reporting, indicating potential limitations in the overall evidence.
https://www.mdpi.com/2079-6382/13/4/364 – This meta-analysis of 9 RCTs involving 1518 participants in the treatment group found that E. purpurea significantly reduced URTI incidence and treatment duration in children (RR = 0.81, 95% CI [0.75; 0.87]). The study assessed the quality of included studies using the PEDro scale and noted a potential for publication bias, which could affect the overall findings.
https://www.preprints.org/manuscript/202502.2015/v1 – This preprint article examines the effects of Echinacea on the common cold. While preprints have not undergone peer review, they can provide preliminary insights into ongoing research. Further validation through peer-reviewed publication is necessary to confirm the findings.
https://sciety.org/articles/activity/10.20944/preprints202502.2015.v1 – This link provides activity and commentary related to the preprint article on Echinacea and the common cold. It offers a platform for discussion and evaluation of the preliminary research findings. As a preprint, the study's conclusions should be interpreted with caution until peer-reviewed publication.